Research profile · Nootropics
Rapastinel (GLYX-13)
NMDA receptor modulator
Available as: 500mg
Overview
A tetrapeptide (Thr-Pro-Pro-Thr-NH₂) derived from a monoclonal antibody, developed as a fast-acting antidepressant.
Mechanism
Modulates the NMDA receptor through a site distinct from ketamine, enhancing synaptic plasticity without ketamine-like dissociative effects.
Research highlights
- Rapid antidepressant effects in phase 2 trials.
- Phase 3 trials as an add-on treatment for depression did not meet their primary endpoints.
Compound data
- Sequence
- Thr-Pro-Pro-Thr-NH₂